• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Advanced lung cancer in the older patient: is there a role for bevacizumab?

作者信息

Marr Alissa S, Ganti Apar Kishor

机构信息

Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA;

出版信息

J Thorac Dis. 2012 Dec;4(6):629-30. doi: 10.3978/j.issn.2072-1439.2012.09.07.

DOI:10.3978/j.issn.2072-1439.2012.09.07
PMID:23205289
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3506784/
Abstract
摘要

相似文献

1
Advanced lung cancer in the older patient: is there a role for bevacizumab?老年患者的晚期肺癌：贝伐单抗是否有作用？
J Thorac Dis. 2012 Dec;4(6):629-30. doi: 10.3978/j.issn.2072-1439.2012.09.07.
2
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.卡铂和紫杉醇联合或不联合贝伐单抗治疗老年晚期非小细胞肺癌患者。
JAMA. 2012 Apr 18;307(15):1593-601. doi: 10.1001/jama.2012.454.
3
Bevacizumab in advanced lung cancer: state of the art.贝伐珠单抗治疗晚期肺癌的现状。
Future Oncol. 2017 Dec;13(28):2515-2535. doi: 10.2217/fon-2017-0302. Epub 2017 Aug 16.
4
Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).一线贝伐珠单抗联合化疗治疗老年晚期或复发性非鳞状非小细胞肺癌的安全性和有效性：阿瓦斯汀在肺癌试验（MO19390）中的安全性。
J Thorac Oncol. 2012 Jan;7(1):203-11. doi: 10.1097/JTO.0b013e3182370e02.
5
First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study.一线贝伐珠单抗治疗晚期非鳞状非小细胞肺癌：SAiL 研究中意大利患者的分析。
Clin Drug Investig. 2012 Nov;32(11):755-60. doi: 10.1007/s40261-012-0001-9.
6
Association of hypertension and treatment outcomes in advanced stage non-small cell lung cancer patients treated with bevacizumab or non-bevacizumab containing regimens.晚期非小细胞肺癌患者使用贝伐单抗或含贝伐单抗方案治疗时高血压与治疗结果的相关性
J Oncol Pharm Pract. 2018 Apr;24(3):209-217. doi: 10.1177/1078155217690921. Epub 2017 Feb 21.
7
Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.多西他赛联合贝伐单抗作为老年晚期非小细胞肺癌一线治疗的可行性研究：胸部肿瘤研究组（TORG）1014。
BMC Cancer. 2015 Oct 19;15:740. doi: 10.1186/s12885-015-1756-1.
8
Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.厄洛替尼治疗后 EGFR 突变阳性晚期非小细胞肺癌化疗初治患者的生存：来自冈山县肺癌研究组试验 1404 的更新。
Jpn J Clin Oncol. 2021 Aug 1;51(8):1269-1276. doi: 10.1093/jjco/hyab084.
9
Bevacizumab in non-small cell lung cancer.贝伐单抗用于非小细胞肺癌的治疗
Drugs. 2008;68(6):737-46. doi: 10.2165/00003495-200868060-00002.
10
Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089).AVAPERL（MO22089）研究中贝伐珠单抗或贝伐珠单抗联合培美曲塞维持治疗晚期非鳞状非小细胞肺癌患者的健康相关生活质量。
J Thorac Oncol. 2013 Nov;8(11):1409-16. doi: 10.1097/JTO.0b013e3182a46bcf.

引用本文的文献

1
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.美国食品药品监督管理局批准摘要：雷莫西尤单抗用于治疗铂类化疗期间或之后疾病进展的转移性非小细胞肺癌。
Oncologist. 2015 Nov;20(11):1320-5. doi: 10.1634/theoncologist.2015-0221. Epub 2015 Oct 7.

本文引用的文献

1
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.卡铂和紫杉醇联合或不联合贝伐单抗治疗老年晚期非小细胞肺癌患者。
JAMA. 2012 Apr 18;307(15):1593-601. doi: 10.1001/jama.2012.454.
2
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.卡铂和每周紫杉醇联合化疗与单药治疗老年晚期非小细胞肺癌的比较：IFCT-0501 随机、3 期试验。
Lancet. 2011 Sep 17;378(9796):1079-88. doi: 10.1016/S0140-6736(11)60780-0. Epub 2011 Aug 8.
3
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer.贝伐珠单抗联合紫杉醇/卡铂治疗晚期非小细胞肺癌的东部肿瘤协作组 E4599 研究中肿瘤组织学的治疗结果。
J Thorac Oncol. 2010 Sep;5(9):1416-23. doi: 10.1097/JTO.0b013e3181da36f4.
4
Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.贝伐珠单抗治疗不可切除性非小细胞肺癌的有效性和安全性：一项荟萃分析。
Clin Drug Investig. 2010;30(4):229-41. doi: 10.2165/11532260-000000000-00000.
5
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.贝伐单抗联合卡铂和紫杉醇治疗老年晚期非小细胞肺癌患者的疗效：东部肿瘤协作组4599试验分析
J Clin Oncol. 2008 Jan 1;26(1):60-5. doi: 10.1200/JCO.2007.13.1144.
6
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.单独使用紫杉醇-卡铂或联合贝伐单抗治疗非小细胞肺癌。
N Engl J Med. 2006 Dec 14;355(24):2542-50. doi: 10.1056/NEJMoa061884.